Substantiation of the target quality profile and risk assessment in the development of a combined drug for injection
DOI:
https://doi.org/10.24959/nphj.22.89Keywords:
sodium hyaluronate; dihydroquercetin; target drug quality profile; Ishikawa diagramsAbstract
Aim. To substantiate the target quality profile for planning the development of a combined drug for injection based on sodium hyaluronate (SH) and dihydroquercetin (DHQ) with an expanded spectrum of the specific activity, as well as to determine the risk factors affecting the quality of the combined drug for injections at the stage of pharmaceutical
development (PD).
Materials and methods. The study objects were the active pharmaceutical ingredients (АРІ) of SH, DHQ and a drug in the form of a solution for injection based on them, as well as potential risk factors affecting the quality of the product. The target product quality profile (QTPP) was developed based on the review and analysis of scientific literature, materials of the State Register of Medicines of Ukraine, pharmacopoeias of the leading countries of the world, articles of scientific publications. The Ishikawa diagram was used to analyze potential risk factors for a drug for injection at the stage of PD.
Results and discussion. The application of scientific approaches to the analysis of scientific materials from various information sources on combination therapy with drugs with multidirectional medicinal substances and the availability of information on parenteral medicines (PM) allowed us to plan a QTPP for the development of a combined drug for injection for intradermal administration. In order to identify the most dangerous factors affecting the quality of the drug, the causal analysis of these factors at the PD stage of the combined drug for injection was carried out, and an Ishikawa diagram was constructed.
Conclusions. The QTPP has been developed. The expected set of quality indicators that would ideally be achieved to ensure the required quality of the drug has been determined taking into account its safety and efficacy. Based on the risk assessment methodology, the Ishikawa diagram for a combined drug for injection has been constructed; potential risks associated with the quality of active ingredients (AI) and excipients, quality of primary packaging, production conditions, quality control of the drug, the technological process affecting the quality of the combined drug for injection and the causes leading to deviations from these indicators have been identified. This diagram is used as a baseline for the overall assessment of quality risks at the stage of drug development.
References
Лікарські засоби. Фармацевтична розробка (ICH Q8) : Настанова СТ–Н МОЗУ 42-3.0:2011 / розроб.: М. Ляпунов та ін. Вид. офіц. Київ : МОЗ України, 2011. 42 с.
Shajeeya A., Viswanath A., Srinivasa R. Quality by Design – Novelty in Pharmaceuticals. World J Pharma Res. 2013. Vol. 2. Iss. 5. Р. 1409–1422.
Kumar V. P., Gupta N. V. A Review on quality by design approach (QBD) for Pharmaceuticals. International Journal of Drug Development & Research. 2015. Vol. 7, Iss. 1. P. 52–60.
Компендиум 2019 – лекарственные препараты / под ред. В. Н. Коваленко. Киев : МОРИОН, 2019. 2480 с. URL: https://compendium.com.ua/about/.
Антиоксидантна композиція для ін’єкцій : пат. 139923 Україна. № u201908006 ; заявл. 12.07.2019 ; опубл. 27.01.2020, Бюл. № 2. URL: https://iprop-ua.com/inv/pdf/6rsvo7gr-pub-description.pdf.
Антиоксидантна композиція для ін’єкцій : пат. 124473 Україна. № a201908004 ; заявл. 12.07.2019 ; опубл. 22.09.2021, Бюл. № 38. URL: https://iprop-ua.com/inv/pdf/rny0l63w-pub-description.pdf.
Державний реєстр лікарських засобів України. URL: http://www.drlz.com.ua/.
Державна фармакопея України : в 3 т. / ДП «Український науковий фармакопейний центр якості лікарських засобів». 2-е вид. Харків: ДП «Український науковий фармакопейний центр якості лікарських засобів», 2014. Т. 2. 724 с.
Державна фармакопея України : в 3 т. / ДП «Український науковий фармакопейний центр якості лікарських засобів». 2-е вид. Харків : ДП «Український науковий фармакопейний центр якості лікарських засобів», 2015. Т. 1. 1128 с.
European Pharmacopoeia. 10h ed. Strasbourg : European Department for the Quality of Medicines, 2020. 2781 p.
Причинно-следственный анализ при оценке рисков на этапе фармацевтической разработки комбинированного препарата для инъекций / М. С. Алмакаев и др. Вестник Фармации. 2018. № 4 (82). С. 74–80.
Загальне оцінювання ризиків для якості на етапі фармацевтичної розробки лікарської форми очні краплі / Л. М. Андрюкова та ін. Управління, економіка та забезпечення якості в фармації. 2014. № 2 (34). С. 6–9.
Лікарські засоби. Управління ризиками для якості (ICH Q9) : Настанова. СТ–Н МОЗУ 42-4.2:2011 / розроб.: ДП «ДНЦЛЗ». Вид. офіц. Київ : МОЗ України, 2011. 26 с.
Semenova K., Almakaievа L. Research of anti-collective activity of a vitro digydroquerceticin solution. Danish Scientific Journal. 2020. Vol. 2, № 35. С. 66–68.
Галлямова Ю. А., Баринова О. А. Структурные и функциональные параметры кожи лица до и после внутридермального введения гиалуроновой кислоты. Косметология. 2012. № 2. С. 52–56.
Papakonstantinou E., Roth M., Karakiulakis G. Hyaluronic acid: A key molecule in skin aging. Dermato-endocrinology. 2012. Vol. 4, Iss. 3. С. 253–258. DOI: https://doi.org/10.4161/derm.21923.
Лич І. В., Угрин А. О., Волошина І. М. Гіалуронова кислота : біосинтез та використання. Український біофармацевтичний журнал. 2019. № 2. С. 6–13. DOI: https://doi.org/10.24959/ubphj.19.212.
Алмакаева Л. Г., Литвинова Е. В. Аргинин и его применение в медицине и фармации. Ліки України. 2011. № 1 (5). С. 23–26.
Трегубова И. А., Косолапов В. А., Спасов А. А. Антиоксиданты: Современное состояние и перспективы. Успехи физиологических наук. 2012. Т. 43, № 1. С. 75–94.
Хабаров В. Н. Гиалуроновая кислота в инъекционной косметологии. Москва : ГЭОТАР-Медиа, 2017. 240 с.
Михайлова Н. П. Влияние интрадермального введения модифицированной гиалуроновой кислоты на морфофункциональное состояние кожи пациенток с инволюционными изменениями. Вестник дерматологии и венерологии. 2013. Т. 89, № 5. С. 152–159. DOI: https://doi.org/10.25208/vdv608.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
